News travels quickly
11.03am
SMH markets live, just in.
Australia is finding out about Mesoblast.
Mesoblast wins approval to treat Australians with COVID trial drug
By Emma Koehn
Australian COVID patients will be able to participate in Mesoblast’s COVID-19 treatment trial after gaining ethics approval this week.
The stem cell treatments business is currently recruiting for a phase 3 study to look at whether its flagship anti-inflammatory product will help reduce respiratory distress in those battling the virus.
The Human Ethics Research Committee at Monash Health has granted hospitals in Melbourne and Sydney approval to be involved in the trial.
Recruitment has already started in the US and the trial will treat 300 patients to establish whether Mesoblast’s treatment works.
Shares were down 0.2 per cent at the market open to $5.23
cheers
Ann: Ethics Approval to Treat COVID-19 Patients in Australia, page-76
-
- There are more pages in this discussion • 245 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |